The prevalence of total hip (THA) and knee arthroplasty (TKA) is growing dramatically, with more than 1 million procedures performed annually in the United States. As the cost of and demand for the newest orthopaedic implants continue to rise, the price paid to medical device companies for implants is a growing concern. Some high-volume healthcare institutions have adopted price capitation strategies to control costs, in which a flat purchase price is negotiated for all implant line items regardless of technology and material. The purpose of this study was to evaluate whether the implementation of price capitation in a large health system affected trends in THA and TKA premium implant selection by surgeons. A secondary objective was to compare selection trends between surgeons with an academic center affiliation and community practice surgeons, within a single health system. All consecutive primary THA and TKA cases six months before (1/1/2011–6/30/2011) and after (8/1/2011–1/31/2012) implementation of a capitated pricing strategy (7/1/2011) were identified. Surgeon education regarding the new pricing policy was conducted for 1-month following implementation, and data during this time were omitted from the study. After exclusions (Figure 1), a total of 481 THA and 674 TKA from the large hospital, and 253 THA and 315 TKA from the two community hospitals comprised the final study cohort. A retrospective review of patient demographics and implant characteristics for each case was performed. Premium THA implants were defined by the existence of one of the following bearing surfaces: second (2G) or third generation (3G) highly cross-linked polyethylene liner with a ceramic or oxidized-zirconium femoral head, ceramic liner with a ceramic femoral head, or mobile-bearing system. Premium TKA implants were defined by the existence of at least one of the following criterion: mobile-bearing design, high-flexion design, oxidized-zirconium femoral component, and/or highly cross-linked polyethylene bearing surface. Pearson's chi-square analyses and Fisher's exact test were used to compare implant usage between pre- and post-capitated pricing time periods.Introduction:
Methods:
Over the last several decades, life expectancy following solid organ transplant (i.e. kidney, liver, heart, lung, and pancreas) has increased significantly, largely due to improvements in surgical technique, immunosuppressive regimens, patient selection, and postoperative care. As this population ages, many of these transplant patients become candidates for total knee arthroplasty (TKA). However, these patients may be at greater risk of complications following TKA due to immunosuppression and metabolic derangements secondary to organ dysfunction. The purpose of this study was to use a large, nationally representative database to compare morbidity, mortality, length of stay (LOS), and charges for TKA patients with and without a history of solid organ transplant. This retrospective study was a review of the Nationwide Inpatient Sample (NIS; the largest all-payer inpatient care United States database representing a 20% stratified sample) from 1998 to 2010. Patients who had a primary TKA (ICD-9-CM 81.54) were included (n = 5,706,675, weighted national frequency). A total of 763,924 cases were excluded for the following: age <18 years, pathologic fracture of lower extremity, malignant neoplasm and/or metastatic cancer, previous and/or bilateral arthroplasty, admission type other than “elective”. The remaining 4,942,751 patients were categorized as transplant (n = 5,245; included only liver, kidney, heart, lung and/or pancreas transplant) or non-transplant group (n = 4,931,017; no history of any transplant including solid organ or tissue). A multivariable regression model was used to identify any association(s) between a history of solid organ transplant and morbidity, mortality, LOS and hospital charges, while adjusting for patient and hospital characteristics.Introduction:
Methods:
Solid organ transplant patients are living longer than in past decades, largely due to improvements in surgical technique, immunosuppressive regimens, patient selection, and postoperative care. As these patients grow older, many of them present for total hip arthroplasty (THA). However, life-long immunosuppressive therapy, metabolic disorders, and post-transplant medications may place transplant patients at higher risk for complications following THA. The objective of this study was to use a national administrative database to compare morbidity, acute complications, in-hospital mortality, length of stay (LOS), and admission costs for THA patients with and without solid organ transplant history. The Nationwide Inpatient Sample (NIS), the largest all-payer inpatient care database representing a 20% stratified sample of United States hospitals, was retrospectively queried for primary THA (ICD-9-CM 81.51) patients from 1998 to 2009 (n = 2,567,930; weighted national frequency). Cases were excluded (n = 324,837) for the following: age <18 years, pathologic fracture of lower extremity, malignant neoplasm and/or metastatic cancer, primary diagnosis of femoral neck fracture, admission type other than “elective,” previous and/or bilateral arthroplasty. The remaining 2,243,093 THA patients were assigned to transplant (n = 6,319; liver, kidney, heart, lung and/or pancreas transplant history) or non-transplant groups (n = 2,231,446; no history of any transplant including solid organ or tissue). Acute complications included a variety of organ-specific and procedure-related complications (i.e. mechanical implant failure, dislocation, hematoma, infection, pulmonary embolism, venous thrombosis). Multivariable regression and general estimating equations were developed to study the effect of transplant history on outcomes, adjusting for patient/hospital characteristics and comorbidity.Introduction:
Methods:
Primary total knee arthroplasty (TKA) is associated with perioperative bleeding, and some patients will require allogenic blood transfusion during their inpatient admission. While blood safety has improved in the last several decades, blood transfusion still carries significant complications and costs. Transfusion indications and alternative methods of blood conservation are being explored. However, there is limited nationally representative data on allogenic blood product utilization among TKA patients, and its associated outcomes and financial burden. The purpose of this study was to use a national administrative database to investigate the trends in utilization and outcomes (i.e. in-hospital mortality, length of stay, admission costs, acute complications) of allogenic blood transfusion in primary TKA patients. The Nationwide Inpatient Sample (NIS), the largest all-payer inpatient care database representing a 20% stratified sample of United States hospitals, was utilized. Primary TKA (ICD-9-CM 81.54) cases from 2000 to 2009 were retrospectively queried (n = 4,544,999; weighted national frequency). A total of 67,841 admissions were excluded (Figure 1). The remaining 4,477,158 cases were separated into two study cohorts: (1) patients transfused with allogenic blood products (red blood cells, platelets, serum) (n = 540,270) and (2) patients not transfused (n = 3,936,888). Multivariable regression and generalized estimating equations were used to examine the effect of transfusion on outcomes, adjusting for patient/hospital characteristics and comorbidity.Introduction:
Methods:
Two-stage revision is considered the gold standard for treatment of knee prosthetic joint infections. Current guidelines for selecting the most appropriate procedure to eradicate knee prosthetic joint infections are based upon the duration of symptoms, the condition of the implant and soft tissue evaluated during surgery and the infecting organism. A more robust tool to identify candidates for two-stage revision and who are at high risk for treatment failure might improve preoperative risk assessment and increase a surgeon's index of suspicion, resulting in closer monitoring, optimization of risk factors for failure and more aggressive management of those patients who are predicted to fail. Charts from 3,809 revision total joint arthroplasties were reviewed. Demographic data, clinical data and disease follow-up on 314 patients with infected total knee arthroplasty treated with two-stage revision were collected. Univariate analyses were performed to determine which variables were independently associated with failure of the procedure to eradicate the prosthetic joint infections. Cox regression was used to construct a model predicting the probability of treatment failure and the results were used to generate a nomogram which was internally validated using bootstrapping.Background
Methods
